DRRX - DURECT Total Debt to Capital
DURECT Corporation (DRRX) generates revenue through the development of epigenetic therapies, specifically treatments for severe metabolic disorders and alcoholic hepatitis; the price action shown below indicates that the separate_debt_total_eq metric stands at 0.53. The company develops new drugs via strategic alliances with pharmaceutical behemoths. Research stability is maintained through globally diversified biomaterial supply chains, which eliminate logistical disruptions.
%20-%20All%20Debt%20to%20Shareholders'%20Equity%20Ratio&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261031&filename=GURU_Markets_-_DRRX_-_DURECT-Corporation_-_All-Debt-to-Shareholders-Equity-Ratio "DRRX (DURECT) Total Debt to Capital history from 07/04/2022 to 09/27/2025 | 👁️GURU.Markets👁️")
Analytical breakdowns for DURECT Corporation
The 0.53 ratio reflects the proportion of debt obligations within the equity structure, allowing for an assessment of financial stability and the business's degree of dependence on creditors. By analyzing the shifting ratio of debt to equity, an investor determines the ability of DURECT Corporation (DRRX) to fund the development of the unique DUR-928 drug for liver tissue regeneration without imposing a critical debt load on the balance sheet.